Patents by Inventor Afshin Samali

Afshin Samali has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Manipulation of HSP70 and IRE1Alpha Protein Interactions
    Publication number: 20130280269
    Abstract: The present invention relates to methods that manipulate the level of interaction between the proteins Hsp70 and IRE1?. In particular, the invention relates to methods of manipulating this interaction in order to increase protein yield, and to methods of manipulating this interaction in order to treat diseases associated with abnormal apoptotic activity, including cancer and autoimmune diseases.
    Type: Application
    Filed: June 8, 2011
    Publication date: October 24, 2013
    Applicant: National University of Ireland
    Inventors: Afshin Samali, Sanjeev Gupta, Aysawaria Deepti
  • Osteopontin for the prediction and treatment of cardiovascular diseases
    Patent number: 8323968
    Abstract: Osteopontin for the prediction and treatment of cardiovascular diseases The present invention relates to the use of endothelial progenitor cells (EPCs) and osteopontin for the treatment of cardiovascular diseases or complications. The invention also relates to the use of EPC osteopontin levels as a marker of the risk of the development of these cardiovascular complications. In particular, the invention provides compositions and methods based on osteopontin and the genes encoding osteopontin.
    Type: Grant
    Filed: March 3, 2008
    Date of Patent: December 4, 2012
    Assignee: National University of Ireland, Galway
    Inventors: Timothy O'Brien, Frank Barry, Aaron Yie Loong Liew, Afshin Samali, Angela Duffy
  • PROTEIN TARGETS IN DISEASE
    Publication number: 20120040906
    Abstract: MicroRNAs have been shown to be critically involved in control of cell survival and cell death decisions. By identifying microRNAs implicated in Endoplasmic Reticulum stress-induced cardiomyocyte apoptosis, it is envisaged that protein targets involved in same can be identified through specifically selected microRNAs. The microRNAs targeted are miR-351, miR-322, miR-125, miR-424 and miR-7a. Furthermore, the potential application of these identified proteins in the treatment of cardiovascular disease, in particular congestive heart failure, is disclosed.
    Type: Application
    Filed: February 26, 2010
    Publication date: February 16, 2012
    Applicant: NATIONAL UNIVERSITY OF IRELAND, GALWAY
    Inventors: Afshin Samali, Sanjeev Gupta
  • TREATMENT OF PROLIFERATIVE DISORDERS WITH A DEATH RECEPTOR AGONIST
    Publication number: 20110262455
    Abstract: A method of treating a proliferative disorder, and a pharmaceutical composition for use in such a method, comprises administering to the patient a combination of an agonist of a death receptor and an antagonist of Egr-1.
    Type: Application
    Filed: October 9, 2009
    Publication date: October 27, 2011
    Applicant: National University of Ireland
    Inventors: Afshin Samali, Eva Szegezdi, Devalingam Mahalingam, Alessandro Natoni
  • CYTOKINE DESIGN
    Publication number: 20110200552
    Abstract: The present invention relates to novel cytokines, which have a modified selectivity/specificity for their cognate receptors. In particular, the invention relates to a variant TRAIL protein, which has superior selectivity for the death receptor 4 (TRAIL-RI) over the death receptor 5 (TRAIL-R2). In addition, the invention relates to a variant TRAIL protein which exhibits superior selectivity for the death receptor 4 (TRAIL-R1) over the decoy receptors DcR1 (TRAIL-R3) and DcR2 (TRAIL-R4).
    Type: Application
    Filed: November 21, 2008
    Publication date: August 18, 2011
    Applicants: RIJKSUNIVERSITEIT GRONINGEN, NATIONAL UNIVERSITY OF IRELAND, GALWAY, TRISKEL THERAPEUTICS B.V, Fundacio Privada Centre De Regulacio Genomica (CRG), Institucio Catalana De Recerca I Estudis Avancats (ICREA)
    Inventors: Carlos Ricardo Rodrigues Dos Reis, Wilhelmus Johannes Quax, Afshin Samali, Eva Szegezdi, Robbert Hans Cool, Albert Martinus Van Der Sloot, Luis Serrano, Vicente Tur
  • Cytokine design
    Patent number: 7994281
    Abstract: The present invention relates to novel methods for the design of proteins, in particular, cytokines. These methods allow the stabilisation of such cytokines, as well as modification of their selectivity/specificity for their cognate receptors. The invention also relates to various modified proteins that have been designed by the methods of the invention.
    Type: Grant
    Filed: December 6, 2004
    Date of Patent: August 9, 2011
    Assignees: European Molecular Biology Laboratory, National University of Ireland, University of Groningen
    Inventors: Vicente R. Tur, Albert Martinus Van der Sloot, Margaret M. Mullally, Robbert H. Cool, Eva E. Szegezdi, Afshin Samali, Gregorio Fernandez-Ballester, Luis Serrano, Wilhelmus J. Quax
  • TRAIL VARIANTS FOR TREATING CANCER
    Publication number: 20110165265
    Abstract: The present invention relates to the use of a mutant TRAIL protein to treat various cancers in mammals. The invention provides a variant TRAIL protein, which has superior selectivity for the death receptor 5, for treating a mammal diagnosed with cancer.
    Type: Application
    Filed: December 17, 2008
    Publication date: July 7, 2011
    Applicants: FUNDACIÓ GENÒMICA (CRG), INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANCATS, NATIONAL UNIVERSITY OF IRELAND, GALWAY, ACADEMISCH ZIEKENHUIS GRONINGEN, RIJKSUNIVERSITEIT GRONINGEN
    Inventor: Afshin Samali
  • Osteopontin for the Prediction and Treatment of Cardiovascular Diseases
    Publication number: 20100150877
    Abstract: Osteopontin for the prediction and treatment of cardiovascular diseases The present invention relates to the use of endothelial progenitor cells (EPCs) and osteopontin for the treatment of cardiovascular diseases or complications. The invention also relates to the use of EPC osteopontin levels as a marker of the risk of the development of these cardiovascular complications. In particular, the invention provides compositions and methods based on osteopontin and the genes encoding osteopontin.
    Type: Application
    Filed: March 3, 2008
    Publication date: June 17, 2010
    Applicant: NATIONAL UNIVERSITY OF IRELAND, GALWAY
    Inventors: Timothy O'Brien, Frank Barry, Aaron Liew Yie Loong, Afshin Samali, Angela Duffy
  • Cytokine Design
    Publication number: 20080044376
    Abstract: The present invention relates to novel methods for the design of proteins, in particular, cytokines. These methods allow the stabilisation of such cytokines, as well as modification of their selectivity/specificity for their cognate receptors. The invention also relates to various modified proteins that have been designed by the methods of the invention.
    Type: Application
    Filed: December 6, 2004
    Publication date: February 21, 2008
    Inventors: Vicente R. Tur, Albert Martinus Van der Sloot, Margaret M. Mullally, Robbert H. Cool, Eva E. Szegezdi, Afshin Samali, Gregorio Fernandez-Ballester, Luis Serrano, Wilhelmus J. Ouax